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????????????
Schizophrenia is considered to be a life-shortening 
illness1）. Several studies have shown that the physical 
health status of patients with schizophrenia is relative-
ly poor and their risk of premature death because of 
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?????????：As the physical health of patients with schizophrenia is relatively poor and their risk of pre-
mature death is considerably increased compared with the general population, we examined the association 
between lifestyle-related diseases and smoking, drinking, and overweight in inpatients and outpatients with 
schizophrenia.
???????：The study design was cross-sectional. Subjects were 138 inpatients and 135 outpatients with 
schizophrenia from a psychiatric hospital in Japan. They were asked for information concerning smoking 
and alcohol use, and height and weight were measured to calculate body mass index. Data on hypertension, 
dyslipidemia, type 2 diabetes, cardiovascular diseases, and use of atypical antipsychotics were acquired from 
medical records.
???????：Inpatients were more likely to receive atypical antipsychotic medication and less likely to drink 
alcohol. The smoking prevalence was 38 .4％ （53.8％ in men, 17 .2％ in women） in inpatients and 39 .3％ 
（56.3％ in men, 20.3％ in women） in outpatients. Multivariate odds ratio （OR） for hypertension was signifi-
cantly higher among outpatients than inpatients. After adjustment for age, sex, and use of atypical antipsy-
chotic medication, overweight smokers showed a significantly higher OR for dyslipidemia （3.17, 95％ CI：
1.07-9.37） among inpatients, and a significantly higher OR for hypertension （3.15, 95％ CI：1.14-8.74） 
among outpatients. When the reference group is non-smokers with BMI below 25, smokers with BMI of 25 
or more had a significant higher OR （3.38, 95％ CI：1.36-8.38） for dyslipidemia among patients with schizo-
phrenia.
??????????：After adjustment for atypical antipsychotic medication use, the combination of smoking and 
overweight was significantly associated with the prevalence of dyslipidemia among inpatients and hyperten-
sion among outpatients with schizophrenia.
???? ????： Schizophrenia, hypertension, dyslipidemia, smoking, antipsychotics
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lifestyle-related diseases is considerably higher than in 
the general population1〜4）. According to previous sur-
veys, the prevalence of metabolic syndrome is higher 
among patients with severe mental illness than among 
the general population5,6）. It is considered that their 
unhealthy lifestyle, such as an unhealthy diet, smoking, 
alcohol consumption, and obesity, is associated with 
the high prevalence of lifestyle-related diseases of this 
population. It has also been reported that atypical an-
tipsychotic medications for patients with schizophrenia 
are associated with obesity and metabolic syndrome7,8）. 
Mental illness is associated with both higher rates and 
higher levels of smoking2,9,10）. Killian et al reported that 
risk of alcohol consumption and smoking were in-
creased in patients with schizophrenia11）.
In this study, we firstly compared the characteristics 
of lifestyle among inpatients with that among outpa-
tients. Although smoking and overweight are well-es-
tablished risk independent factors for lifestyle-related 
diseases, to our knowledge, few studies have investi-
gated the combined risk of smoking and overweight 
for lifestyle-related diseases among psychiatric pa-
tients. Therefore, in this study, we examined the asso-
ciation between lifestyle-related diseases and smoking, 
and overweight in patients with schizophrenia. We hy-
pothesize that patients with schizophrenia who smoke 
and are overweight have a high prevalence of life-
style-related diseases.
???????
This study was conducted within a cross-sectional 
survey of psychiatric inpatients and outpatients of a 
psychiatric hospital in Japan, from 2007 to 2008. After 
written informed consent was obtained from all partici-
pants who could understand the meaning of this sur-
vey, they were asked for information about smoking, 
alcohol use, habitual exercise, and intake of healthy 
foods. Data regarding the presence or absence of hy-
pertension, dyslipidemia, type 2 diabetes, cardiovascu-
lar diseases, and the use of atypical antipsychotics 
were acquired from the participants’ medical records. 
Participants’ weight and height were measured, and 
body mass index （BMI） was calculated as weight/
height2 （kg/m2）. A BMI of 25 or more was defined as 
excessive weight. This cross-sectional psychiatric sur-
vey was approved by the ethical review board of Dok-
kyo Medical University and a director of the psychiat-
ric hospital where the survey was conducted.
The subjects of the present study were 138 inpa-
tients （80 men, 58 women） and 135 outpatients （71 
men, 64 women） with schizophrenia who had no miss-
ing values from the psychiatric hospital survey men-
tioned above. Thus, data regarding the presence or ab-
sence of hypertension, dyslipidemia, type 2 diabetes, 
and cardiovascular diseases, use of atypical antipsy-
chotics and self-reported lifestyle behaviors were 
available for all subjects. Patients were diagnosed ac-
cording to the International Classification of Disease 
（ICD）-10 criteria of the World Health Organization12） 
with the use of structured clinical interviews by psy-
chiatric specialists. Schizophrenia included schizotypal 
and delusional disorders （ICD F20-F29）.
We examined the association between disease （such 
as hypertension, dyslipidemia, type 2 diabetes, and car-
diovascular diseases） and lifestyle （such as smoking, 
BMI, smoking combined with excessive weight, and 
use of atypical antipsychotics）. We did not analyze the 
data regarding habitual exercise and intake of healthy 
foods since these lifestyle-related factors, as well as al-
cohol consumption, differed greatly between inpatients 
and outpatients.
The characteristics of inpatients and outpatients 
were compared by chi-square, Fisher’s exact, and t-
tests. Then, multivariate odds ratios （ORs） among all 
patients for hypertension, type 2 diabetes, dyslipi-
demia, and cardiovascular diseases were calculated by 
binary logistic regression analysis. Each OR was calcu-
lated using binary logistic regression analysis among 
inpatients or outpatients adjusted by age, sex, and use 
of atypical antipsychotics. Statistical significance was 
defined as p＜0.05 . All data were analyzed using the 
software Statistical Package for Social Sciences （SPSS, 
16.0J for MAC）.
???????
Table 1 shows the characteristics of inpatients and 
outpatients with schizophrenia. Inpatients were more 
likely to receive atypical antipsychotic medication （p＜
0.001）. There were no significant differences in the 
prevalence of hypertension, dyslipidemia, type 2 diabe-
tes, and cardiovascular diseases between inpatients 
and outpatients. The smoking prevalence of inpatients 
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was 38.4％ （53.8％ in men, 17.2％ in women） and that 
of outpatients was 39 .3％ （56.3％ in men, 20 .3％ in 
women）, showing no significant difference. As only 
two inpatients habitually consumed alcohol, there was 
a large significant difference between the proportion of 
drinkers among inpatients and outpatients. Over-
weight patients were more prevalent among outpa-
tients （47.4％） than inpatients （39.9％）, although this 
difference was not significant （p＝0.224）.
Table 2 shows multivariate ORs for hypertension, 
type 2 diabetes, dyslipidemia, and cardiovascular dis-
eases among all patients. Overweight inpatients had a 
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????????Characteristics of inpatients and outpatients with schizophrenia
Inpatients
（n＝138）
Outpatients
（n＝135）
p-value
Mean age（SD） 53.5（12.8） 50.5（13.2） 0.056
Mean BMI（SD） 23.86（4.26） 24.85（4.34） 0.059
Men 80（58.0％） 71（52.6％） 0.396
Hypertension 20（14.5％） 31（23.0％） 0.088
Dyslipidemia 19（13.8％） 29（21.5％） 0.112
Type 2 diabetes 24（17.4％） 20（14.8％） 0.623
Cardiovascular diseases  8（ 5.8％）  3（ 2.2％） 0.217
Smoking  53（38.4％） 53（39.3％） 0.902
BMI ≥ 25  55（39.9％） 64（47.4％） 0.224
Smoking with excessive weight  27（20.0％） 28（20.3％） 1.000
Drinking alcohol   2（ 1.4％） 24（17.8％） ＜0.001＊＊＊
Use of atypical antipsychotics 112（81.2％） 81（60.0％） ＜0.001＊＊＊
＊＊＊p＜0.001, by chi-square, Fisher’s exact, or t-tests
???????　 Adjusted odds ratios for hypertension, type 2 diabetes, dyslipidemia, and 
cardiovascular diseases among patients with schizophrenia by logistic regression 
analysis （n＝273）
Hypertension Type 2 
diabetes
Dyslipidemia Cardiovascular 
diseases
OR
（95％ CI）
OR
（95％ CI）
OR
（95％ CI）
OR
（95％ CI）
Inpatients 1.00 1.00 1.00 1.00
Outpatients 2.01 0.57 1.46 0.39
（1.01–4.04）＊ （0.19–1.67） （0.74–2.89） （0.09–1.68）
Smoking status 1.00 1.00 1.00 1.00
Non-smoker 1.77 1.03 1.25 2.05
Current smoker （0.84–3.72） （0.49–2.16） （0.62–2.52） （0.45–9.28）
BMI
＜25 1.00 1.00 1.00 1.00
≥ 25 1.17 1.56 2.32 1.28
（0.60–2.28） （0.80–3.05） （1.20–4.47）＊ （0.34–4.82）
Atypical 
antipsychotics
No 1.00 1.00 1.00 1.00
Yes 0.69 0.81 0.56 1.57
（0.23–1.40） （0.39–1.70） （0.27–1.14） （0.35–7.02）
95％ CI, 95％ confidence interval；OR：odds ratio adjusted for age, sex, smoking status, 
BMI, and use of atypical antipsychotics；＊ p＜0.05-by binary logistic regression
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significantly higher OR for dyslipidemia （2.32 , 95％ 
CI：1.20-4 .47）. Outpatients had a significant higher 
OR （2.01, 95％ CI：1.01-4.04） for hypertension than 
inpatients. Among inpatients with schizophrenia, over-
weight smokers had a significantly higher OR for dys-
lipidemia （3.17, 95％ CI：1.07-9.37）, as shown in Ta-
ble 3. Moreover, overweight smokers had the highest 
adjusted OR for cardiovascular diseases （5.50 , 95％ 
CI：0.93-32.33）. Among outpatients with schizophre-
nia, overweight smokers had a significantly higher OR 
for hypertension （3.15, 95％ CI：1.14-8.74）, as shown 
in Table 4. Additionally, outpatients receiving atypical 
antipsychotic medication had a significantly lower OR 
for type 2 diabetes （0.34, 95％ CI：0.13-0.99）.
Adjusted odds ratios for hypertension, type 2 diabe-
tes, dyslipidemia, and cardiovascular diseases among 
all patients in relation to combination of smoking and 
overweight are shown in Table 5. The reference group 
is non-smokers with BMI below 25 . Smokers with 
BMI of 25 or more had a significantly higher OR （3.38, 
95％ CI：1 .36-8 . 38） compared with the reference 
group. The combination of smoking and overweight 
showed higher, but not significantly higher, ORs for 
hypertension, type 2 diabetes, or cardiovascular diseas-
es compared with other groups.
??????????
The results of our study show that the combination 
of smoking and overweight was significantly associat-
ed with prevalence of dyslipidemia among inpatients 
and prevalence of hypertension among outpatients 
with schizophrenia. The combination of smoking and 
overweight showed a strong association with preva-
lence of dyslipidemia. Akbartabartoori et al reported 
that the combination of smoking and overweight or 
obesity aggravated cardiovascular disease risk factors, 
particularly HDL-cholesterol and C-reactive protein13）. 
To our knowledge, however, the present study is the 
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???????　 Adjusted odds ratios for hypertension, type 2 diabetes, dyslipidemia, and 
cardiovascular diseases among inpatients with schizophrenia by logistic 
regression analysis （n＝138）
Hypertension Type 2 
diabetes
Dyslipidemia Cardiovascular 
diseases
OR
（95％ CI）
OR
（95％ CI）
OR
（95％ CI）
OR
（95％ CI）
Smoking status
Non-smoker 1.00 1.00 1.00 1.00
Current smoker 3.07 0.57 0.87 5.02
（0.86-11.30） （0.19-1.67） （0.29-2.58） （0.78-32.2）
BMI
＜25 1.00 1.00 1.00 1.00
≥ 25 1.02 1.20 2.20 2.27
（0.35-2.95） （0.48-3.00） （0.82-5.95） （0.54-10.41）
Smokers with
BMI ≥ 25 
No 1.00 1.00 1.00 1.00
Yes 0.99 1.14 3.17 5.50
（0.24-4.10） （0.36-3.58） （1.07-9.37）＊ （0.93-32.33）
Atypical 
antipsychotics
No 1.00 1.00 1.00 1.00
Yes 0.77 1.70 0.73 3.15
（0.23-2.75） （0.97-2.99） （0.20-2.69） （0.31-31.78）
95％ CI, 95％ confidence interval； OR： odds ratio adjusted for age, sex, and use of atypical 
antipsychotics；＊ p＜0.05-by binary logistic regression
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first targeting patients with schizophrenia to show an 
association between lifestyle-related diseases and the 
combination of smoking and overweight.
The smoking prevalence was 38.4％ （53.8％ in men, 
17.2％ in women） in inpatients and 39.3％ （56.3％ in 
men, 20 .3％ in women） in outpatients in the present 
study, which was higher than the smoking prevalence 
among Japanese （39.4％ in men, 11.0％ in women） ac-
cording to the Japanese National Health and Nutrition 
Survey in 200714）. In the United States, the prevalence 
of smoking among patients with schizophrenia was re-
ported to be 68％ , which was significantly higher than 
that of controls （35％）2）, while a German study report-
ed such prevalence among patients with schizophrenia 
at 68.8％ and that of the general population at 32.2％
11）. Campo-Arias et al reported that the smoking prev-
alence among patients with schizophrenia was 26％ 
（34.8％ in men, 11 .0％ in women） and that smoking 
was associated with schizophrenia but not with mood 
disorders15）.
Killian et al also reported that risk of alcohol con-
sumption was increased among patients with schizo-
phrenia and depression11）, although patients with 
schizophrenia were less likely to drink alcohol in our 
study. As the inpatients of psychiatric hospitals are 
prohibited from drinking alcohol in Japan, this indi-
cates that many outpatients continued with their ces-
sation of alcohol consumption after hospitalization. The 
results of our study are in agreement with a report 
that patients with schizophrenia consume less alcohol 
but smoke more than the general population16）.
Coodin reported that patients with schizophrenia 
had significantly higher BMI than the general popula-
tion17）. Obesity was more prevalent among individuals 
with mental illness than among the general population, 
and was associated with adverse health outcomes in-
cluding diabetes and hypertension18）. One of the risk 
factors for weight gain in patients with mental illness 
is the use of atypical antipsychotic medication 19）. 
Weight gain after taking antipsychotics was reported 
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???????　 Adjusted odds ratios for hypertension, type 2 diabetes, dyslipidemia, and 
cardiovascular diseases among outpatients （n＝135）
Hypertension Type 2 
diabetes
Dyslipidemia Cardiovascular 
diseases
OR
（95％ CI）
OR
（95％ CI）
OR
（95％ CI）
OR
（95％ CI）
Smoking status
Non-smoker 1.00 1.00 1.00 1.00
Current smoker 1.60 1.65 1.66 ─
（0.63-4.06） （0.57-4.81） （0.67-4.10）
BMI
＜25 1.00 1.00 1.00 1.00
≥ 25 1.02 2.00 2.32 0.33
（0.29-1.66） （0.48-3.00） （0.97-5.59） （0.02-4.96）
Smokers with
BMI ≥ 25 
No 1.00 1.00 1.00 1.00
Yes 3.15 1.14 1.72 ─
（1.14-8.74）＊ （0.36-3.58） （0.65-4.59）
Atypical 
antipsychotics
No 1.00 1.00 1.00 1.00
Yes 0.77 0.34 0.42 0.43
（0.23-1.57） （0.13-0.99）＊ （0.18-1.00） （0.03-6.14）
95％ CI, 95％ confidence interval；OR： odds ratio adjusted by age, sex, and use of atypical 
anti psychotics；＊ p＜0.05 by binary logistic regression
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to be related to reduced levels of adiponectin7）. There-
fore, the use of atypical antipsychotic medication was 
taken into consideration in the present study. Howev-
er, in our study, use of atypical antipsychotic medica-
tion was a negative risk factor for lifestyle-related dis-
eases, especially type 2 diabetes among outpatients. 
Because the side effects of atypical antipsychotics are 
well known, psychiatric doctors tend not to prescribe 
these agents to patients with type 2 diabetes. Clini-
cians should screen and monitor carefully for cardio-
metabolic side effects and risk factors for comorbid 
conditions8,20）.
The results of our study show that the combination 
of smoking and overweight was significantly associat-
ed with the prevalence of dyslipidemia among inpa-
tients and the prevalence of hypertension among out-
patients with schizophrenia. Therefore, it is important 
for psychiatric inpatients and outpatients to change to 
healthier behaviors to prevent lifestyle-related diseas-
es. Thus, current smokers should be encouraged to 
participate in smoking cessation programs, and those 
who are overweight should be introduced to weight 
loss programs.
Patients with schizophrenia who are diagnosed with 
and treated for lifestyle-related diseases have difficulty 
in changing unhealthy habits such as smoking and be-
ing overweight. However, weight management and 
lifestyle advice should be routinely offered to all pa-
tients with schizophrenia21）. Weiser et al suggested 
that a general strategy of health promotion for people 
with mental disorders should take into account behav-
ioral, environmental, and iatrogenic health risks 22）. 
Health promotion programs should be tailored to the 
needs and abilities of each psychiatric patient. Kita-
bayashi et al reported that 3 months after a trial of in-
stitutional smoking prohibition, the smoking rate de-
creased from 36 . 3％ to 2 2 . 2％, but no significant 
increase in BMI was observed23）. Although institution-
al smoking prohibition is a good way to introduce a 
smoking cessation program into the health education 
provided by psychiatric hospitals, self-motivation to 
stop smoking is more important. Therefore, cessation 
advice and appropriate follow-up care should be pro-
vided to psychiatric patients24）.
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???????　 Adjusted odds ratios for hypertension, type 2 diabetes, dyslipidemia, and 
cardiovascular diseases among inpatients and outpatients in relation to the 
combination of smoking and overweight （n＝273）
Hypertension Type 2 
diabetes
Dyslipidemia Cardiovascular 
diseases
OR
（95％ CI）
OR
（95％ CI）
OR
（95％ CI）
OR
（95％ CI）
Non-smoker 
with BMI＜25 1.00 1.00 1.00 1.00
（n＝102）
Smokers with 1.44 1.48 1.61 1.66
BMI ≥ 25 （0.49-4.24） （0.44-5.02） （0.51-5.14） （0.11-24.82）
（n＝52）
Non-smoker 
with BMI 0.84 1.57 2.08 0.64
≥ 25 （0.35-2.05） （0.66-3.75） （0.86-5.03） （0.10-4.14）
（n＝64）
Smokers with 
BMI ≥ 25 2.04 1.63 3.38 2.99
（n＝55） （0.77-5.40） （0.64-4.19） （1.36-8.38）＊ （0.50-18.04）
95％ CI, 95％ confidence interval； OR： odds ratio adjusted by age, sex, inpatients or 
outpatients, and use of atypical anti-psychotics； ＊ p＜0.05 by binary logistic regression
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As this study’s design was cross-sectional and ex-
amined one point in time, the associations observed in 
this study do not indicate causality of lifestyle-related 
diseases. Thus, a further large-scale longitudinal study 
will be needed to explore the combined risk of smok-
ing and overweight on lifestyle-related diseases among 
individuals with and without schizophrenia. Moreover, 
an intervention study involving health education to 
schizophrenic patients is warranted.
Nevertheless, this is the first study to show an asso-
ciation between lifestyle-related diseases and the com-
bination of smoking and excessive weight among pa-
tients with schizophrenia. The results of our study 
suggested that the introduction of programs to stop 
smoking and lose weight is very important for patients 
with schizophrenia.
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